Please assess the completion status of the following clinical trial:

Trial Title: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with documented disaccharidase assay levels of lactase, sucrase, maltase, and palatinase via EGD disaccharidase assay (DA) performed no more than 1 year prior to enrollment with normal histological interpretation. Eligible subjects will be enrolled into the following study groups based on their documented sucrase level.~* DA Sucrase \< 25 (n=500)~* DA Sucrase 25-35 (n=500)~* DA Sucrase \>55 (n=100)~* At the discretion of the investigator, subject is suspected of CSID and has at least one symptom of diarrhea, abdominal pain, gas/bloating, nausea, or borborygmi at least 3x per week for the past 3 months or more.~* Subject or parent/guardian must provide informed consent/assent prior to any study procedures being performed.~* Subject is a U.S. resident.~* Subject is male or female, ages 6 months to 17 years old.~* Subject/parent or guardian is willing and able to complete necessary study procedures including following study instructions, completing electronic questionnaires via a personal mobile device, attending study visits and, in the Investigator's judgment, is sufficiently stable to participate in the study.~* Subject/ parent or guardian must be able to read or understand the English language.~* Subject or parent/guardian must have their own Android or Apple device for BYOD.~Exclusion Criteria:~* Females who are lactating or pregnant.~* Subjects with allergy to sucrose, yeast, papain, or glycerol.~* Subjects with causes of abdominal pain or altered bowel habits other than CSID such as inflammatory bowel disease, celiac disease, eosinophilic gastrointestinal disorder, pancreatitis, or gastrointestinal bleeding.~* Subjects with a history of diabetes mellitus.~* Subjects with a recent febrile illness (5 days prior to study).~* Subjects that do not have the mental capacity to understand the study requirements and are unable to comply.~* Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.~* Subject has previously used Sucraid®.~* Subject has uncontrolled systematic disease.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Open Labeled Commercial Sucraid (Type: EXPERIMENTAL): All subjects will complete a 7-day treatment period of open-labeled FDA approved commercial Sucraid.

Based on this trial design, predict the completion outcome and termination type (if applicable).